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Background: Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common
subtype of extranodal non-Hodgkin lymphoma (NHL), with rituximab, cyclophosphamide,
doxorubicin, vincristine and prednisone (R-CHOP) as the commonly used treatment regimen.
However, full cycles of standard R-CHOP present the risk of severe bleeding or perforation, even
leading to emergency surgery, especially for those with deep lesions in their first 1–2 cycles of
treatment. This study aims to explore the safety and efficacy of fractioned R-CHOP (rituximab
d0, 50% dose of CHOP d1 and d5) followed by standard R-CHOP cycles in PG-DLBCL patients
guided by endoscopic ultrasonography (EUS).
Patients and Methods: Thirty-one PG-DLBCL patients were analyzed in this retrospec-
tive study. All patients had lesions infiltrated to at least the 3rd layer of the stomach under
EUS at baseline. Patients switched to standard R-CHOP if they showed the reduced
infiltrated layers and restricted lesions after fractioned R-CHOP cycles.
Results: The overall response rate, 5-year progression-free survival (PFS) and overall
survival (OS) of patients in our study were 93.5%, 75% and 84%, respectively. No treatment
delay or dosage reduction from gastric adverse event was observed. None of the patients in
our study suffered from severe bleeding or perforation during the treatment. Kaplan–Meier
analyses showed that PG-DLBCL patients characterized by multiple localization, lesions
≥3cm, having B symptoms, lower serum albumin level, and elevated LDH level were
associated with worse PFS and OS.
Conclusion: Our data indicate that it might be an effective approach in treating deeply
infiltrated PG-DLBCL patients by switching fractioned R-CHOP to standard R-CHOP cycles
guided by EUS.
Keywords: primary gastric diffuse large B-cell lymphoma, endoscopic ultrasonography,
R-CHOP, prognosis
Background
Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is one of the most
common extranodal non-Hodgkin lymphomas (NHLs).1 Treatment of the disease
includes surgery, chemotherapy, and radiotherapy, alone or combined. And the best
regimen has not been standardized. The general consensus is that treatment should
be given concerning the principal clinical issues of patients, and the biological
behavior of the malignancies, which guide the doctors to decide whether to offer
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local-therapy or systemic chemotherapy.2–4 Six to 8 cycles
of rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone (R-CHOP) are usually used to treat the
disease. However, full cycles of standard R-CHOP
(Rituximab d0, 100% dose of CHOP d1) present the risk
of severe bleeding or perforation, even leading to emer-
gency surgery, especially for those with deep lesions in
their first 1–2 cycles of treatment. Fractioned R-CHOP
which could increase the safety of treatment has been
investigated and applied in clinical practice in recent
years.5 However, considering the probability that frac-
tioned R-CHOP might cause resistance to the treatment,
the optimal proportion of fractioned dose and applied
cycle is unclear at present.
Endoscopic ultrasonography (EUS) has emerged as one
of the best tools for loco-regional staging in PG-DLBCL
patients. It also has a predictive value in diagnosis, eval-
uating treatment response and post-treatment follow-up.6,7
EUS could visualize the 5-layer structure of the stomach,
provide important information on prognostic features of
PG-DLBCL patients and may contribute to the determina-
tion of the therapeutic approach.
In the current study, we retrospectively reviewed
a cohort of primary gastric diffuse large B-cell lymphoma
patients treated with early fractioned R-CHOP (Rituximab
d0, 50% dose of CHOP d1 and d5) and were then switched
to a standard R-CHOP cycle, guided by EUS. This study




We retrospectively reviewed patients that were pathologi-
cally confirmed as gastric diffuse large B-cell lymphoma
and were treated in the Shanghai Cancer Center, China,
from October 2011 to October 2018. The inclusion criteria
for patients in our study were as follows: 1) age range 18- to
75-years-old; 2) histologically confirmed, previously
untreated primary gastric diffuse large B-cell lymphoma; 3)
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (PS) of 0–2; 4) had EUS examination before
treatment, and had lesions infiltrated to at least the 3rd layer
of the stomach (5 layers in total) at baseline; and 5) received
fractioned R-CHOP as an initial treatment. This study was
approved by the Institutional Review Board of the Fudan
University Shanghai Cancer Center. And all patients signed
informed consent forms for reviewing their medical records
and research. Baseline clinicopathological features, labora-
tory assessments were reviewed and obtained from the
hospital database and are summarized in Table 1. Survival
data were available with a median follow-up of 513 days
(range 105~2607 days).






> 60 15 48.4
≤ 60 16 51.6
Lugano stage
I 4 12.9
II 1 6 19.4
II 2 11 35.5
II E 1 3.2
IV 9 29.0








≥ 2 10 32.3
ALB
≤35 3 9.7
> 35 28 90.3
LDH









Mean±SD 17.92 ± 10.49
Abbreviations: ALB, albumin; LDH, lactic dehydrogenase; CHOP, cyclophospha-
mide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab, cyclophospha-
mide, doxorubicin, vincristine, and prednisone.
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Treatment
Patients received full-dose-intensity R-CHOP with frac-
tioned infusion of cyclophosphamide, doxorubicin and vin-
cristine on days one and five, respectively (rituximab
375mg/m2 d0, cyclophosphamide 375mg/m2 d1 and d5,
doxorubicin 25mg/m2 d1 and d5, vincristine 1mg d1 and
d5, prednisone 100mg d1-5). The cycles were repeated
every 3 weeks. Abdominal symptoms and signs, and fecal
occult blood tests were carefully monitored during treat-
ment. The response evaluation was performed by an
enhanced CT as well as EUS every 2 or 3 cycles. Patients
switched to standard R-CHOP cycles (rituximab 375mg/m2
d0, cyclophosphamide 750mg/m2 d1, doxorubicin
50mg/ m2 d1, vincristine 1.4mg/m2 with a maximal dose
of 2mg, d1, and prednisone 100mg d1-5) if they got com-
plete response (CR) or partial response (PR) at the evalua-
tion and showed reduced infiltrated layers (≤2nd layer of
stomach) with restricted lesions. All patients were treated
with 6 or 8 cycles, if tolerated. Awhole-body PET-CT scan
was given at the end of the treatment. Granulocyte colony-
stimulating factor (G-CSF) could be administered by sub-
cutaneous injection during myelosuppression. Prophylaxis
usage of G-CSF is also recommended.
Assessment of Response and Adverse
Event
All patients received a whole-body PET-CT scan, enhanced
abdominal or gastric CT, as well as EUS at baseline before
treatment. The response evaluation was performed by an
enhanced CT as well as EUS every 2 or 3 cycles. PET-CT
was applied in 4–6 weeks after the last chemotherapy
course of R-CHOP regimen. Response criteria were
adapted from the international consensus reported by
Cheson et al.8 After the completion of therapy, follow-ups
were carried out on patients every 3 months for the first two
years, and every 6 months for the next 3 years, and annually
thereafter. The follow-up visits included a physical exam-
ination, routine blood tests, enhanced CT of the involved
area, and a gastroscopy.
Adverse events during treatment were evaluated
according to the National Cancer Institute common toxi-
city criteria scale (version 4.0).
Statistical Analysis
All analyses were performed using PASW Statistics 18 (SPSS
Inc., Chicago). Kaplan–Meier survival curves were con-
structed for survival analyses, and differences were tested by
the Log rank test. OS was defined as the time between the date
of diagnosis and the date of death or the date of last contact.
PFS refers to the period from the diagnosis to the observed
progression of the disease or the occurrence of death for any
reason. The data of patients alive at the end of the study were
censored. All P values were two-sided, and the results were
considered significant if P < 0.05.
Results
Patient Characteristics
Flow-charts of all patients with primary gastric diffuse large
B-cell lymphoma at our hospital treated during the period
was described in Figure 1. During the period, 81 PG-DLBCL
patients were treated. Forty-three patients underwent EUS at
baseline, among whom 31 had deeply infiltrated lesions and
accorded with the inclusion criteria of this study and retro-
spectively enrolled. All 31 cases were from hospitalized
patients, of whom 15 (48.4%) were men and 16 (51.6%)
were women. The median age was 54 years (range 18 to
75 years). According to the 1994 Lugano modifications of
the Musshoff staging classification,9 21 patients (67.8%)
were diagnosed with stage I and II disease, 1 (3.2%) and 9
(29.0%) patients were diagnosed with stage IIE and IV dis-
ease, respectively. Symptoms of the patients with this disease
were unspecific. The most common were abdominal pain or
discomfort, gastric hemorrhage, lack of appetite and weight
loss. Basic features of the patients are recorded concerning
the clinical/pathological parameters of tumors (Table 1). We
found that 13 (41.9%) patients had lesions more than one site
of stomach. And the most frequent site of PG-DLBCL in our
study was the body of the stomach (Table 2).
Treatment Effect and Response of the
Patients
None of the patients in our study underwent surgery at the
onset of disease. All 31 patients received initial fractioned
R-CHOP (Rituximab d0, 50% dose of CHOP d1 and d5) for
at least 2 cycles. Patients switched to standard R-CHOP if
they showed the reduced infiltrated layers and restricted
lesions under EUS after fractioned R-CHOP cycles.
Twenty-three (74.2%) patients successfully switched to
standard R-CHOP after 2 cycles of fractioned R-CHOP
regimen. Three (9.7%) patients received 3 cycles of frac-
tioned R-CHOP and then switched to standard R-CHOP
course. Another 4 (12.9%) patients had 4 cycles of frac-
tioned R-CHOP and then switched. Only 1 (3.2%) patient
got progression of disease (PD) after two cycles of
Dovepress Liu et al
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fractioned R-CHOP treatment. All together, 29 patients
received R-CHOP*6, and 2 patients had R-CHOP*8. The
overall response rate of the patients was 93.5% (29/31). The
CR and PR rate of patients were 80.6% (25/31) and 12.9%
(4/31), respectively. No treatment delay or dosage reduction
from gastric adverse event was observed. More importantly,
no patients in our study suffered from severe bleeding or
perforation during the treatment. Five-year PFS and 5-year
OS were 75% and 84%, respectively. Three (9.7%) patients
had died of the disease at the date of last follow-up. OS and
PFS of all patients in our study were showed in Figure 2.
The adverse events during treatment are presented in
Table 3. Haematological toxicity was the predominant adverse
event. Grade 3/4 neutropenia occurred in 35.5% of the patients
and febrile neutropenia in one patient (3.2%). Pneumonia and
nausea were the top two non-hematologic toxicities. We
observed no treatment-related deaths in our study.
Effect of Clinicopathological Parameters
on PFS and OS of PG-DLBCL Patients
Kaplan–Meier analyses showed that PG-DLBCL patients
characterized by late stage (stage IV) (P = 0.025), multiple
localization (sites > 1) (P = 0.049), large size (P = 0.004),
higher international prognostic index (IPI) score (P= 0.048),
having B symptoms (P < 0.001), lower serum albumin
(ALB) level (P < 0.001), and elevated lactate dehydrogenase
(LDH) level (P = 0.045) had shorter PFS (Figure 3). And
patients with multiple localization (P= 0.032), large
size (≥ 3cm) (P = 0.044), and deep lesions (≥ 11mm)
(P = 0.031) under EUS, having B symptoms (P < 0.001),
lower ALB level (≤ 35g/L) (P < 0.001), and elevated LDH
level (> 250U/L) (P = 0.012) associated with worse OS
(Figure 4).
Figure 1 Flow-charts of patients with primary gastric diffuse large B-cell lymphoma (PT-DLBCL) who were treated at our department between October 2011 and
October 2018. Eighty-one PG-DLBCL patients were treated during the period. Forty-three patients underwent endoscopic ultrasonography (EUS) at baseline, among whom
12 were treated with standard R-CHOP cycles, and 31 had deeply infiltrated lesions and were initially treated with fractioned R-CHOP regime and were then switched to
standard R-CHOP cycles guided by EUS.
Table 2 Features of the Lesion in PG-DLBCL Patients Receiving
EUS Before Treatment








Depth (n = 30)
< 11mm 18 60.0
≥ 11mm 12 40.0




Liu et al Dovepress
submit your manuscript | www.dovepress.com
DovePress



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Discussion
DLBCL is a common subtype of primary gastric lym-
phoma. PG-DLBCL has been treated with various modal-
ities, such as surgery, chemotherapy and radiotherapy,
alone or in combination. Traditionally, radical gastrectomy
was regarded as the front-line treatment for PG-DLBCL
patients. In recent years, surgery is given only to patients
with a massive bleed or perforation at presentation.4
Besides, surgery could lower the quality of life and post-
pone the beginning of chemotherapy. R-CHOP is now
considered to be the standard regimen to treat the
disease.10–13 However, management of deeply infiltrated
PG-DLBCL patients is still challenging as it has high
incidence of bleeding as well as perforation during treat-
ment, which might be fatal. In our study, we evaluated the
feasibility and efficacy of switching fractioned R-CHOP to
standard R-CHOP to treat this subset of patients.
PG-DLBCL lesions, large in size and deep under the
EUS, had a greater risk of bleeding or perforation during
treatment, and patients often suffered worse PFS and OS.
Full cycles of standard R-CHOP (Rituximab d0, 100% dose
of CHOP d2) had the risk of severe bleeding or perforation,
potentially leading to emergency surgery, especially for those
with large and deep lesions in their first 1–2 cycles of
treatment.14–17 It is known that dose intensity of chemother-
apy is crucial in the treatment of lymphoma. As it is defined
as the average weekly dose of chemotherapy drugs per
square meter of body surface area in the whole treatment
course, we fractioned conventional R-CHOP to day one
and day five in order not to reduce patients' dose-intensity.
There were also studies of splitting R-CHOP to day one
and day two in older patients.5 We believe it is more rational
to split on day one and day five, as doctors can closely
monitor routine blood tests and fecal blood tests after the
Figure 2 Progression-free survival (PFS) and overall survival (OS) of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients in our study. Kaplan–Meier curves
show the PFS (A) and OS (B) of the PG-DLBCL patients in our study.
Table 3 Adverse Event from Chemotherapy and Event Grade
Toxicity No. of Events % Grade1+2 No. of Events % Grade 3+4
Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
Neutropenia 7 5 38.7 7 4 35.5
Anemia 3 4 22.6 0 0 0
Thrombocytopenia 4 1 16.1 1 0 3.2
Febrile neutropenia – – – 1 0 3.2
Nonhematologic
Nausea 3 1 12.9 0 0 0
Increased ALT/AST 2 0 6.5 0 0 0
Pneumonia 0 5 16.1 0 0 0
Dovepress Liu et al
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50%CHOP on the first day of treatment. All patients enrolled
in our study had a high possibility of perforation and bleeding
during treatment. However, after applying the initial treat-
ment of fractioned R-CHOP, no adverse effects, such as
bleeding or perforation, were observed. However, full cycles
of fractioned R-CHOP might cause resistance to the treat-
ment. Switching fractioned R-CHOP to standard R-CHOP
could provide a balance between treatment effects and the
avoidance of severe side effects. In our study, patients
switched in good time to the standard R-CHOP cycle when
lesions were restricted under EUS evaluation.
EUS is a valuable tool in the diagnosis of PG-DLBCL
patients, as it could diagnose and utilize the loco-regional
staging of the disease. Furthermore, EUS could measure
the invasive depth of lesions, this could not be accom-
plished by an ordinary gastroscopy. Our previous work
provided new insights about evaluation of PG-DLBCLs
based on EUS results. PG-DLBCL patients having lesions
with large size (≥3cm), or deep depth (≥11mm) were more
inclined to have a worse OS.18 This study further extends
its role in the guidance of treatment when switching to
standard R-CHOP regimens.
In our previous work, we illustrated some prognostic fac-
tors of PG-DLBCL patients. In this study, we also confirmed
that a tumor located at multiple sites of the stomach, having
B symptoms, lower ALB levels and an elevated LDH level
could act as adverse prognostic biomarkers. Besides, the tumor
size and depth as examined by endoscopic methodology were
valuable parameters to predict the outcomes of PG-DLBCL
patients.
To our knowledge, this is the first study including only
deeply infiltrated PG-DLBCL patients (infiltrated ≥ 3rd layer
of the stomach under EUS). The ORR, 5-year PFS and 5-year
OS of patients in our study were 93.5%, 75% and 84%,
respectively. Concerning safety parameters, the most com-
mon adverse event was neutropenia. It could successfully be
addressed through using growth factors or dose modifica-
tions. Other common AEs were grade 1 or grade 2 anemia,
thrombocytopenia, and nausea. All the toxicities, but pneu-
monia, were tolerable without interruption of treatment.
Our data indicate that an effective and tolerable
approach in treating deeply infiltrated PG-DLBCL patients
is by switching fractioned R-CHOP cycles to standard
R-CHOP cycles, guided by EUS. We cannot deny some
limitations of this study, such as the relatively small num-
ber of patients, the retrospective analysis, the single insti-
tution study, as well as a relatively short follow-up period.
However, our work might shed light on novel treatment
strategies in treating the disease. More prospective, multi-
center clinical trials are still needed.
Figure 3 Correlation of clinical and laboratory parameters on progression-free survival (PFS) of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) patients. Kaplan–
Meier curves show the association between stage (A), location (B), size (C), international prognostic index (IPI) (D), B symptoms (E), serum albumin (ALB) level (F), lactate
dehydrogenase (LDH) level (G) and PFS of PG-DLBCL patients in our study. All the P values are shown in the graph, by Log rank test.
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